SG11201509924WA - Composition for maintaining function of platelets - Google Patents

Composition for maintaining function of platelets

Info

Publication number
SG11201509924WA
SG11201509924WA SG11201509924WA SG11201509924WA SG11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA
Authority
SG
Singapore
Prior art keywords
platelets
composition
maintaining function
maintaining
function
Prior art date
Application number
SG11201509924WA
Other languages
English (en)
Inventor
Shinji Hirata
Takahiko Murata
Koji Eto
Original Assignee
Kaken Pharma Co Ltd
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd, Univ Kyoto filed Critical Kaken Pharma Co Ltd
Publication of SG11201509924WA publication Critical patent/SG11201509924WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
SG11201509924WA 2013-06-07 2014-06-06 Composition for maintaining function of platelets SG11201509924WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013120696 2013-06-07
PCT/JP2014/065061 WO2014196624A1 (fr) 2013-06-07 2014-06-06 Composition pour maintenir la fonction plaquettaire

Publications (1)

Publication Number Publication Date
SG11201509924WA true SG11201509924WA (en) 2016-01-28

Family

ID=52008253

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509924WA SG11201509924WA (en) 2013-06-07 2014-06-06 Composition for maintaining function of platelets

Country Status (9)

Country Link
US (1) US20160168540A1 (fr)
EP (1) EP3006029A4 (fr)
JP (1) JPWO2014196624A1 (fr)
KR (1) KR20160018517A (fr)
CN (1) CN105392482B (fr)
AU (1) AU2014275836A1 (fr)
CA (1) CA2914326A1 (fr)
SG (1) SG11201509924WA (fr)
WO (1) WO2014196624A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
JP6584956B2 (ja) 2012-12-21 2019-10-02 アステラス インスティテュート フォー リジェネレイティブ メディシン 多能性幹細胞から血小板を生産するための方法およびその組成物
ES2865854T3 (es) * 2016-09-23 2021-10-18 Kaken Pharma Co Ltd Método para producir (r)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]imidazolidin-2,4-diona y un producto intermedio para producir la misma
CN115657634B (zh) * 2022-09-30 2024-06-04 重庆赛力斯凤凰智创科技有限公司 汽车软件架构、模块关联方法、计算机设备和存储介质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058064B2 (en) 2006-10-04 2011-11-15 The University Of Tokyo Sac-like structure enclosing hematopoietic progenitor cells produced from ES cells and method for preparing blood cells
WO2009119105A1 (fr) 2008-03-28 2009-10-01 国立大学法人東京大学 PROCÉDÉ DE PRÉPARATION IN VITRO DE PLAQUETTE GPIBα+GPV+GPVI+
WO2009122747A1 (fr) 2008-04-01 2009-10-08 国立大学法人東京大学 Procédé de préparation de plaquette à partir de cellule ips
WO2012036257A1 (fr) * 2010-09-17 2012-03-22 国立大学法人東京大学 Composition destinée à maintenir la fonction plaquettaire
US9447072B2 (en) * 2011-12-09 2016-09-20 Kaken Pharmaceutical Co., Ltd. Pyridone derivative and pharmaceutical containing same
TWI636782B (zh) * 2013-06-07 2018-10-01 科研製藥股份有限公司 （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥

Also Published As

Publication number Publication date
CN105392482B (zh) 2017-08-08
JPWO2014196624A1 (ja) 2017-02-23
EP3006029A1 (fr) 2016-04-13
KR20160018517A (ko) 2016-02-17
EP3006029A4 (fr) 2017-01-04
CA2914326A1 (fr) 2014-12-11
WO2014196624A1 (fr) 2014-12-11
US20160168540A1 (en) 2016-06-16
AU2014275836A1 (en) 2015-12-24
CN105392482A (zh) 2016-03-09

Similar Documents

Publication Publication Date Title
GB201319525D0 (en) Composition
EP2889350A4 (fr) Composition collante-adhésive
HRP20181710T1 (hr) Uporaba derivata benzimidazol-prolina
EP3006525A4 (fr) Composition d'asphalte-uréthane
GB201319540D0 (en) Composition
GB201318489D0 (en) Composition
GB201317388D0 (en) Composition
GB201306984D0 (en) Composition
EP3066178A4 (fr) Composition lubrifiante
GB201320303D0 (en) Composition
GB201319538D0 (en) Composition
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
GB201317196D0 (en) Composition
GB201307622D0 (en) Composition
SG11201509924WA (en) Composition for maintaining function of platelets
HRP20182110T1 (hr) Sastav spojeva tiakumicina
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition
GB201318394D0 (en) Composition
HK1204865A1 (en) Composition for elimination of troublesome varmints
KR102216470B9 (ko) 천연물 조성물
GB201305622D0 (en) Composition
HK1198422A1 (en) Novel uses of colossolactones
GB201315461D0 (en) Composition of phosphonates
PL3071575T3 (pl) Wytwarzanie normorfinanów